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IN VIVO PROTECTION WITH HUMAN MONOCLONAL ANTIBODY S315 FOLLOWING 
CHALLENGE WITH DIPHTHERIA TOXIN 
 
Heidi L. Smith, MD, PhD1; Maria Lobikin, PhD1; Wenda Gao, PhD2; Greg Saia, PhD1, Yang 
Wang, PhD1, Mark Leney, PhD1, Deborah C. Molrine, MD, MPH1 
1MassBiologics of UMMS, Boston, MA; 2Antagen Pharmaceuticals, Boston, MA 
 
Background: Morbidity and mortality from Corynebacterium diphtheriae is reduced by prompt 
administration of equine-derived diphtheria anti-toxin (DAT), which is in short supply worldwide. 
MassBiologics has developed a human monoclonal antibody (S315) to diphtheria toxin to 
provide a safer alternative to DAT and address critical supply issues.  S315 prevents toxin 
binding to its putative host receptor and S315 pre-mixed with toxin increased survival in a 
guinea pig model of intoxication.  To further evaluate the ability of S315 to provide in vivo 
protection, we established a post-exposure treatment model. 
 
Methods: Female Hartley guinea pigs (300-350g) were challenged subcutaneously with 
diphtheria toxin (0.03 to 0.09 Lf, limit of flocculation) to identify the minimum lethal dose.  To 
evaluate anti-toxin efficacy, DAT or S315 was administered five hours post-toxin challenge and 
animals monitored for 30 days for signs of illness (lethargy, dehydration, weak limbs).  Serum 
anti-diphtheria toxin antibodies were measured by ELISA and Vero cell toxin neutralization 
assays. 
 
Results:  The minimum lethal toxin dose was 0.09 Lf.  To determine the protective dose of 
DAT, 0.2 IU, 1.0 IU or 5.0 IU was administered intravenously post-toxin challenge (n=4/cohort).  
All 0.2 IU or 1.0 IU DAT-treated animals died, while one animal treated with 5.0 IU survived.  
DAT was subsequently evaluated at 5.0 IU, 10 IU, and 20 IU and compared to a cohort 
receiving 3.5 mg of S315.  All untreated animals died within 72 hours and all antibody-treated 
animals survived. Dehydration was observed more frequently in the 5 IU and 10 IU DAT cohorts 
compared to the 20 IU and S315 cohorts. 
 
Conclusions: Treatment with S315 after diphtheria toxin exposure is protective; further studies 
will define a minimum effective dose of S315.  This model mimics the route and timing of anti-
toxin treatment in humans and provides a rigorous preclinical evaluation of a human antibody 
replacement for equine DAT.  
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